CEFUROXIME PANPHARMA 750 MG

Country: Israel

Language: English

Source: Ministry of Health

Active ingredient:

CEFUROXIME AS SODIUM

Available from:

PHARMALOGIC LTD

ATC code:

J01DC02

Pharmaceutical form:

POWDER FOR SOLUTION FOR INJ/INF

Composition:

CEFUROXIME AS SODIUM 750 MG/VIAL

Administration route:

I.M, I.V

Prescription type:

Required

Manufactured by:

PANPHARMA LABORATORIES, FRANCE

Therapeutic group:

CEFUROXIME

Therapeutic area:

CEFUROXIME

Therapeutic indications:

Infections caused by susceptible microorganisms, prophylaxis against post operative infections in a variety of operations.

Authorization date:

2023-12-31

Summary of Product characteristics

CEFUROXIME PANPHARMA 750 MG
1.
NAME OF THE MEDICINAL PRODUCT
Cefuroxime Panpharma 750 mg
Powder for Solution for Injection /Infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Vials containing 750 mg sterile Cefuroxime as Cefuroxime sodium.
Sodium content per vial: 38.62 mg
3.
PHARMACEUTICAL FORM
Cefuroxime is a white to faintly-yellow powder to which appropriate
amounts
of water are added.
4.
CLINICAL PARTICULARS 4.1 INDICATIONS
_ _
_RESPIRATORY TRACT INFECTIONS _
For example, acute and chronic bronchitis, infected bronchiectasis,
bacterial pneumonia, lung abscess and post-operative chest infections.
_ _
_EAR, NOSE AND THROAT INFECTIONS _
For example, sinusitis, tonsillitis, pharyngitis and otitis media.
_ _
_URINARY TRACT INFECTIONS _
For example, acute and chronic pyelonephritis, cystitis and
asymptomatic bacteriuria.
_ _
_SOFT TISSUE INFECTIONS _
For example, cellulitis, erysipelas, peritonitis and wound infections.
_ _
_BONE AND JOINT INFECTIONS _
For example, osteomyelitis and septic arthritis.
_ _
_OBSTETRIC AND GYNECOLOGICAL INFECTIONS; PELVIC INFLAMMATORY DISEASES;
GONORRHOEA _
Particularly when penicillin is unsuitable.
_ _
_OTHER INFECTIONS _
Including septicemia and meningitis.
_ _
_PROPHYLAXIS _
Against infection in abdominal, pelvic, orthopedic, cardiac,
pulmonary, oesophageal and
vascular surgery where there is increased risk of infection.
4.2 DOSAGE AND ADMINISTRATION
GENERAL DOSAGE RECOMMENDATIONS
_ _
_ADULTS _
Many infections will respond to 750 mg three times daily by IM or IV
injection. For more
severe infections, this dose should be increased to 1.5 g three times
daily. IV. The
frequency of IM or IV injections can be increased to six-hourly if
necessary, giving total
doses of 3 g to 6 g daily.
_ _
_INFANTS AND CHILDREN _
Doses of 30 to 100 mg/kg/day given as three or four divided doses. A
dose of 60
mg/kg/day will be appropriate for most infections.
_ _
_NEONATES _
Doses of 30 to 100 mg/kg/day given as two or three divided doses. In
the first weeks of life
the serum half-life of cefuroxime c